Drugs / l-LV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03992911 | Jun 2019 → Jun 2022 | neuroendocrine carcinoma | Peking University | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | l-LV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03992911 ↗ |